How To Slow Biological Aging With a Multivitamin, Vegetables, & Omega-3 | Dr. Steve Horvath
In a Nutshell
Dr. Steve Horvath explains that epigenetic clocks like GrimAge and DunedinPACE reliably track mortality risk and intervention effects by measuring DNA methylation patterns that integrate inflammation, metabolic stress, and other aging processes. Multivitamins, omega-3 supplementation, vegetable intake (via carotenoids), and weight loss each slow epigenetic aging by a few months over 1–3 years, with stronger effects in people starting from poorer health. While clocks detect real biological changes from these accessible interventions, they miss some aging mechanisms like cellular senescence and telomere attrition, so they should complement—not replace—other health measures.
These notes were generated by AI and may contain inaccuracies.
Dr. Steve Horvath, professor of human genetics and developer of the Horvath epigenetic aging clock, explains that his core question as a longevity researcher is what drives aging. The Horvath clock has become a landmark finding in biomedicine for measuring biological aging.
The COSMOS trial showed that participants given a multivitamin slowed their brain aging by 2.1 years. Mental health and social relationships also emerged as surprising factors that translate to measurable changes on the DNA molecule in blood.
Biological age refers to the phenomenon that people of the same chronological age have different mortality and morbidity risks, or appear older or younger than peers. Longevity researchers and geroscientists measure biological age using technologies such as step counts, gait speed, imaging data for brain age, and molecular markers.
Horvath works on epigenetic marks, specifically DNA methylation. The signal for aging and mortality is very strong in methylation patterns. Biological age measurement requires examining multiple levels: molecular readouts (gene expression, proteome, metabolome, glycome), biochemical readouts (blood biochemistry), organ function measures (fibrosis), and functional measures (VO2 max, gait speed, daily living activities, frailty).
Horvath's work was motivated by understanding aging even in people who optimize lifestyle and prevention. Methylation clocks track damage accumulation that occurs despite healthy behaviors and that drives organ dysfunction years or decades later. The goal is to create a precise tool for identifying interventions that can reverse the age of individual cells, organs, and the whole organism.
A common misconception is that all biological aging clocks should agree and produce one unified readout. This expectation is unreasonable because methylation changes occur at millions of DNA locations. Different clocks capture different properties of aging: some track inflammation well, others track metabolic syndrome or stressors like smoking.
First-generation clocks primarily measure calendar age. Second-generation clocks relate to inflammation, metabolic syndrome, and stressors. The metaphor used is proteomics: just as different proteins measure different things, different methylation locations produce different readouts. Most clocks were developed for blood for convenience, but organ-specific and single-cell clocks are now being developed.
The PhenoAge clock was a major advance for mortality risk prediction. It was constructed to track biochemical markers and changes in blood cell composition that reflect organ dysfunction. The goal was to create a methylation surrogate of clinical parameters. This clock proved to be an impressive mortality risk predictor.
The GrimAge clock (named after the Grim Reaper) superseded PhenoAge and remains highly impressive for mortality risk prediction. It was published in 2019 and was developed in Horvath's lab by Ake Lu. GrimAge was constructed by combining methylation estimators of various biomarkers (including C-reactive protein as a marker of chronic inflammation and smoking history) in an optimal linear combination to predict mortality risk.
Methylation-based estimates of C-reactive protein correlate only modestly (around 0.3) with plasma levels, yet the methylation estimate is a far better predictor of mortality risk. Similarly, methylation-based estimates of smoking exposure outperform self-reported smoking pack years for predicting lifespan. This principle underlies GrimAge: methylation estimators of known biomarkers are combined to create superior mortality predictors.
Methylation clocks strongly predict mortality risk and are now used in randomized controlled trials. Startups are exploring their use for life insurance pricing. Methylation is thought to track long-term stressor exposures because the epigenome functions as a memory system that remodels regulatory pathways in response to prolonged stress.
Studies from the Netherlands (Dutch Hunger Winter) examined whether periods of starvation could alter the gonadal methylome and affect offspring. These findings remain controversial, with strong counterarguments existing. Horvath emphasizes remaining neutral on whether parental exposures definitively affect offspring outcomes, noting that rigorous peer-reviewed studies exist on both sides.
Sperm methylation patterns change with age, but the locations differ completely from those used in standard epigenetic clocks. Applying GrimAge, PhenoAge, or the original Horvath pan-tissue clock to sperm yields uninformative results (everyone receives essentially the same number). Specific clocks have been developed for sperm. The same principle applies to placenta: clocks exist for estimating gestational age and maternal stressors, but they target different methylation locations than adult tissue clocks.
Two years ago, Horvath would have been cautious about whether GrimAge changes are reversible. Current evidence from rigorous randomized controlled trials with supplements and medications shows that GrimAge can be reversed to some extent, though the changes appear minor. This represents a hopeful message for interventions.
The DunedinPACE clock measures the pace of aging.
DunedinPACE was developed by Dr. Moffett and Dan Bellski as an odometer-style clock measuring the speed or pace of aging rather than the accumulation of damage. The team examined rates of change in physiologic and biochemical markers including body mass index, waist-to-hip ratio, glucose impairment, and markers of inflammation. The study leveraged the Dunedin cohort in New Zealand, a longitudinal study tracking middle-aged and younger people over many years with repeated assessments. Multiple measurements per person enabled estimation of each individual's aging trajectory. The researchers then used methylation to estimate the pace of aging based on these physiological measures.
People use DunedinPACE along with other clocks when studying interventions. The best interventions touch on many clocks, indicating robust rejuvenation of the methylome. The main clocks appearing in the literature are PhenoAge, GrimAge or GrimAge2, and DunedinPACE.
When an intervention shows a 2% slowing of the pace of aging in a 6-month trial, it may not yet register in GrimAge due to trial duration and the standard deviation of the measurement. Strong interventions are expected to affect multiple correlated clocks. After regressing out age, sex, and other variables, clocks show a correlation around 0.5, indicating reasonable agreement.
GrimAge performed best for mortality risk prediction in large studies including Generation Scotland (18,000 people) and a Harvard study (30,000 people). GrimAge serves as a surrogate for all-cause mortality in observational data on diet and lifestyle, allowing shorter intervention trials to estimate mortality effects without waiting decades.
The longevity field aims to develop surrogate endpoints for clinical trials. The FDA has not yet approved any biomarker as an official surrogate endpoint for mortality. While not formally validated, methylation clocks track validated interventions known to benefit human mortality risk in the expected direction, increasing confidence in their utility. The field cannot wait for full regulatory approval given urgent questions about interventions.
HIV-positive individuals show pronounced epigenetic age acceleration of five to seven years in blood. Antiretroviral therapy reverses this acceleration by four to five years, with effects appearing within several weeks to a month. This finding is well-established across multiple studies worldwide.
Anti-TNF alpha therapy, an anti-inflammatory treatment for autoimmune disease, also shows strong evidence of affecting epigenetic age. Metformin shows weaker effects on epigenetic age compared to these medical interventions.
Omega-3 and multivitamins demonstrate beneficial effects on epigenetic age, though the magnitude is much smaller, typically a couple of months of rejuvenation.
Claims of reversing biological age by five years in seven months through lifestyle interventions require scrutiny of baseline BMI and other clinical readouts. Such effects are more plausible when starting from a highly unhealthy state with obesity, inflammation, diabetes, and accelerated GrimAge. A person starting eight years older than expected on GrimAge might return to average through comprehensive lifestyle changes including GLP-1 agonists, exercise, and dietary improvements.
For already healthy biohackers claiming five-year reversals from minor diet changes, skepticism is warranted. Rejuvenating interventions tend to show stronger effects in people with accelerated epigenetic age and weaker or absent effects in already healthy individuals.
Vitamin D deficiency is associated with age acceleration. Correcting deficiencies through weight loss, physical activity, smoking cessation, healthy eating, and micronutrient repletion produces more robust effects on aging markers. Once sufficient levels are achieved, additional supplementation does not further slow aging.
Insurance companies predict lifespan using traditional readouts including blood pressure, medical history, prior cancer, and substance abuse. GrimAge adds predictive value beyond these variables but the incremental benefit is modest. The test costs several hundred dollars, raising cost-benefit questions for both companies and consumers.
GrimAge estimates instantaneous mortality hazard rather than a literal death date. A 50-year-old with GrimAge eight years older than chronological age has more than twice the risk of dying in the next year compared to an average same-age, same-sex peer. The estimate carries a substantial error bar of approximately plus or minus six years. It is unethical and scientifically unsound to translate GrimAge directly into a predicted death date due to this uncertainty and the complexity of human life events.
Epigenetic clocks relate to mitochondrial dysfunction and energetics, stem cell biology, metabolic changes and nutrient sensing, and aspects of DNA repair. They also reflect changes in cell composition, including shifts toward stressed memory T cells, cytotoxic T cells, and exhausted T cells, as well as inflammation.
Clocks function as integrators of multiple stressors but have notable blind spots. They do not capture cellular senescence well. Radiation-induced senescence and double-strand breaks do not produce corresponding methylation changes. Telomere biology shows only weak correlation with most clocks. Overexpression of telomerase did not produce beneficial effects in vitro studies.
Epigenetic clocks should be complemented with other readouts because they do not capture the totality of aging processes. Certain aspects of DNA repair relate to epigenetic aging while others do not.
Epigenetic clocks such as GrimAge, DunedinPACE, and PhenoAge track inflammation to some extent. However, it would be a grave error to assume that the clocks only measure inflammation biology. The clocks very much relate also to stem cell functioning and other aspects, functioning as integrators of multiple biological processes.
There are interventions that don't even touch the inflammasome but could have a very strong effect on reversing epigenetic age. One prime example would be therapies that completely rejuvenate hematopoietic stem cells. If bone marrow is replaced with hematopoietic stem cells that have an epigenetic age of zero, this would rejuvenate the blood drastically.
Mouse studies and human studies show that the epigenetic age in a bone marrow transplant recipient often reflects the age of the donor.
When asked whether rejuvenating the blood might also rejuvenate other organs, the response is to assume not. Animal studies from Vadim Gladyshev's lab at Harvard on hematopoietic stem cell transplantation have been disappointing. They didn't rejuvenate other organs, and after a number of months the stem cells had aged because the body has the memory of the old mouse.
Vadim Gladyshev carried out elegant transplantation experiments addressing whether replacing the blood of an old mouse with that of a very young mouse, or replacing other organs like the kidney or heart, would translate to body-wide rejuvenation. The current reading of the literature is that researchers haven't found any such organ as a target.
There was some evidence from heterochronic parabiosis studies where young blood put into older mice rejuvenated the brain, with cognitive function improving on a battery of tests.
Heterochronic parabiosis, where the circulation of an old mouse is connected with a young mouse, is one of the best paradigms of rejuvenation, arguably along with caloric restriction. When an old mouse is exposed to the circulation of a young mouse, it has multiple benefits including cognitive benefits and muscle benefits. Epigenetic clocks get rejuvenated in many organs, including the liver and kidney, on the methylation level.
However, when the mice are disconnected and no longer exposed to the young circulation, the epigenetic age bounces back to that of the recipient mouse. This is a very common story in the longevity field: a powerful intervention rejuvenates the organ, but the effect is transient.
Caloric restriction is mentioned as a rejuvenating therapy. The CALERIE trial was a two-year randomized control trial where individuals were eating 25% fewer calories than they otherwise would. The US population in the trial is assumed to be on the chubby side. Adherence was not good, and the age reduction was very weak.
Multiple blood draws allowed evaluation of which methylation clocks pick up a beneficial effect. GrimAge and PhenoAge did not pick up an effect, but DunedinPACE really picked it up, showing roughly a 2 to 3% slowing of the rate of aging over the two years.
DunedinPACE was developed to track changes in BMI, which explains why it picked up the weight loss effect. GrimAge was trained on mortality, not weight loss. The other clocks likely did not pick it up due to sample size issues or small effect size.
A study involving obese people with BMI 30 and higher who were put on semaglutide treatment showed these people lost a lot of weight over 33 weeks. The study was published as a preprint by Michael Kley's group in San Diego. All methylation clocks picked up the effect with a large sample size.
If there is a strong weight loss intervention with strong reduction in fat, lipolysis reduces the inflammatory signal, and all methylation clocks will pick it up. Obesity accelerates aging and is associated with decreased life expectancy, increased cardiovascular disease, type 2 diabetes, and cancer.
Different clocks have different specialties. GrimAge and PhenoAge found an effect based on multivitamin use, but DunedinPACE failed to reach statistical significance. The field now simply reports at least five clocks so readers can judge for themselves.
The COSMOS trial involved three randomized control trials where older adults were given a standard Centrum Silver multivitamin every day for 3.6 years. People given the multivitamin slowed their brain aging by 2.1 years. Episodic memory aging was slowed by almost 5 years compared to the placebo group. Participants did better on a battery of cognition tests.
On epigenetic aging clocks, PhenoAge and GrimAge were the ones that stood out, showing slowing of aging by roughly 2.7 months to 5 months over the two-year period measured.
If the effect of slowing aging by 3 to 5 months within a 2-year range is sustained over 20, 30, or 40 years, these benefits accumulate. For a 50-year-old using a multivitamin until age 80, the expectation is a benefit of roughly two and a half years. The effect is minor, but the effort of taking a multivitamin is minimal.
The COSMOS trial looked at cancer mortality, cardiovascular mortality, and all-cause mortality, and those didn't show statistically significant changes within the timeframe examined. Epigenetic clocks and brain aging effects showed signals before hard endpoints.
This study was viewed as a triumph for epigenetic clocks. Large-scale studies were initiated because vitamins are important and avoiding deficiencies is important. Hard endpoints like mortality and cardiovascular disease didn't detect an effect, which was deeply frustrating.
Five years ago, a consumer looking at the literature would not take a multivitamin due to no benefit shown on hard endpoints. Now epigenetic clocks picked up the signal even though it was weak. All-cause mortality is a hard and definitive readout, but people die for a hundred different reasons that may not relate to the biology of aging.
Multivitamins serve as an insurance policy to fill nutritional gaps. Many people globally are not getting enough vitamins, minerals, trace elements, and essential fatty acids from their diet. The intervention is safe.
Ninety percent of Americans don't get enough omega-3 fatty acids. Observational studies cannot be trusted, but a rigorous randomized controlled trial, placebo-controlled trial was published last year by Swiss professor Heike Bischoff-Ferrari. The study looked at 780 people aged 71 years or older with an average age of around 73-75.
The interventions evaluated were omega-3 at 1 gram, vitamin D, and exercise. The vitamin D intervention was high vitamin D at 2,000 IUs versus low vitamin D at 800 IUs. Results for vitamin D were disappointing with no effect on epigenetic clocks.
The home exercise intervention was mild resistance training three times a week. The starting population had around 88% already identifying as physically active, which limited the ability to see effects. No effect was found, which was disappointing.
The most credible result was omega-3 on epigenetic clocks. A couple of epigenetic clocks picked it up including GrimAge version 2, PhenoAge, and DunedinPACE. The treatment arm where people used all three interventions—high dosage vitamin D, omega-3, plus exercise—did the best according to PhenoAge. There was a dose-dependent effect where the group that got omega-3 and vitamin D improved more than omega-3 alone, and all three interventions improved the most.
A study demonstrated a dose-dependent effect when adding healthy lifestyle interventions to an already healthy population. The intervention delayed biological aging by 3.8 months over three years as measured by PhenoAge. This was associated with a 61% reduced chance of developing metastatic cancer and a 20% reduction in pre-frailty. The same study showed improvements in intrinsic capacity, which encompasses domains of functioning including frailty, cognition, and psychology.
Even in a population that was already 88% physically active, meaningful improvements were observed. The compounding effect of starting such interventions earlier in life, such as in one's 20s, 30s, or 40s, and maintaining them over decades could produce substantial long-term benefits.
A study comparing 800 IU to 2,000 IU of vitamin D showed no major difference because most participants started with normal vitamin D levels and were not deficient. Multiple studies have shown that vitamin D deficiency can cause age acceleration of up to 3 years, and correcting the deficiency slows or reverses this acceleration. The Berlin BASE-II study was notable because it included both deficient and sufficient populations and followed participants for 7 years. Benefits were observed only in the deficient group, confirming that vitamin D is not a magic supplement but rather corrects existing deficiencies.
Factors affecting vitamin D status include gene SNPs and magnesium levels, since magnesium is required to convert vitamin D3 into its active steroid hormone form. Baseline and follow-up measurements are essential before drawing conclusions about vitamin D interventions.
Weight loss acts as a major confounder in dietary pattern trials. When overweight participants adopt Mediterranean or other healthy diets, weight loss occurs across interventions, making it difficult to isolate the effects of the diet itself from the effects of weight reduction.
GrimAge correlates strongly with blood carotenoid levels, an objective marker of fruit and vegetable consumption. Food questionnaires are often unreliable due to memory bias and social desirability. In postmenopausal women from the Women's Health Initiative, carotenoid levels showed a strong negative correlation of -0.3 with GrimAge. For comparison, smoking shows a correlation of 0.4, while exercise shows a weaker correlation of 0.1. This indicates vegetable intake has a substantially stronger effect on epigenetic aging than exercise.
This finding prompted increased vegetable consumption. Carotenoids such as lutein and zeaxanthin accumulate in the eye and brain, supporting eye health, preventing age-related macular degeneration, and improving cognitive function and crystallized intelligence. Other carotenoids include beta-carotene and lycopene. These compounds buffer oxidative stress and singlet oxygen.
A vegan trial showed slower epigenetic aging compared to omnivores, though weight loss was a confounding factor. Analysis of 3,000 women in the Women's Health Initiative found only a negligible effect of red meat consumption on epigenetic age. Personal dietary patterns include meat and vegetables with reduced simple carbohydrates.
Large-scale studies across Japan, Germany, and the US using wearable step counts found a weak correlation of -0.1 between physical activity and epigenetic clocks, requiring thousands of participants to detect statistically significant effects. This was considered disappointing given exercise's known broad benefits.
Muscle methylation clocks from human biopsies have not yet convincingly demonstrated exercise effects. A 2025 study by Vanam examined a more intensive intervention: participants bicycled 4.5 hours per week for 6 months. This produced a 20% improvement in VO2 max and a 7.4-month reduction in PC-GrimAge (principal component-based GrimAge), a more robust version of GrimAge with lower test-retest variability. Participants were aged 30-65.
A two-year randomized controlled trial in previously sedentary 50-year-olds involving approximately 5 hours per week of cycling, high-intensity interval training, and some resistance training improved heart structure to resemble that of a 30-year-old, representing approximately 20 years of structural reversal.
The intensive cycling study lacked a control arm. Epigenetic clocks may require a threshold of exercise intensity and volume to detect effects. Deliberate heat exposure via sauna or hot tub can elevate heart rate and produce physiological changes similar to moderate-intensity cardiovascular exercise, including improved blood pressure and resting heart rate.
A Harvard study by Sinisa Veratin stimulated pre-optic neurons in mice to lower body temperature by approximately 3°C, resulting in substantially slower aging across multiple organs as measured by methylation clocks. Hibernation studies in marmots at UCLA showed that methylation clocks did not advance during hibernation periods.
Observational data from the Women's Health Initiative linked severe sleep disruptions to increased epigenetic age. No studies have yet correlated specific sleep stages such as deep sleep or REM sleep duration with epigenetic aging measures. Chronic sleep deprivation increases inflammation, alters appetite, and promotes weight gain.
A Harvard researcher, Laura Kachinsky, examined social cumulative advantage, measuring community connection, social behavior, and relationships with friends, family, and spouse. Loneliness is recognized as a mortality risk comparable to smoking. The study measured cortisol, stress hormones, inflammatory markers including IL-6, and methylation. Despite skepticism that social factors would translate to detectable DNA methylation changes in blood, the analysis proceeded with adequate funding.
Social advantage from strong family relations and community connections reduces GrimAge. The methylation readout showed stronger effects than other biological markers in this study. Loneliness increases stress and acts as a major killer in old age, particularly among geriatric patients whose friends have often died.
Japan has deployed robots to entertain and engage isolated elderly patients. While this approach may seem culturally alienating to Western audiences, it represents an opportunity for AI and robotics to provide companions and address urgent engagement needs. Ideally, family members would visit geriatric patients, but this is not always realistic. Jobs dealing with geriatric patients are often underpaid with staffing shortages, requiring creative solutions.
Epigenetic clocks provide concrete numbers to understand how lifestyle factors affect biological aging. The tests are available to consumers, though researchers primarily use them. Different people have different priorities: weight loss for overweight individuals, smoking cessation for smokers, sleep improvement, or exercise. People interested in optimizing their aging can establish a baseline with DNA GrimAge testing to measure biological age and track improvements.
Epigenetic tests cost several hundred dollars. People do not need measurements to know they should stop smoking, exercise, and eat vegetables, but longevity doctors report that epigenetic clock measurements improve adherence to regimens. Cheaper readouts around $50 are technologically possible but not yet available. Lower-cost tests may use less-characterized clocks without the same legacy data from the past decade.
Reliable tests use the Illumina array technology, which follows standardized protocols with years of research on data preprocessing and signal optimization versus technical noise. The five main clocks (including DNA GrimAge, PhenoAge, DunedinPACE) all use this technology, enabling leverage of legacy data to assess effects of vegetables or exercise. As long as a lab has experience generating these data, results are reliable. Providers offer the Horvath clock plus approximately 100 readouts including protein markers like CRP and plasminogen activator inhibitor 1.
Recent innovations allow methylation to estimate ages of different organs, showing whether the heart, kidney, or lung is biologically older. These consumer-available tests can generate 50-100 page reports. Users do not need to obsess over analysis providers since they can access raw data and upload it to web-based calculators for latest tool applications. The Epigenetic Clock Foundation offers one such calculator.
A key medical use case involves identifying people who age faster to determine interventions. For already-optimized individuals, new regimens would be needed to observe methylation changes. Measurements should not occur during illness.
PC GrimAge shows high reproducibility with technical variation of a few months when measured days apart. DunedinPACE is slightly less robust but maintains high technical reproducibility. Different clock types measure different biological aspects and can produce discrepant results. The Horvath pan-tissue clock excels for stem cell biology and hematopoietic stem cell precursors of leukemia but performs poorly for mortality risk prediction.
Both DunedinPACE and DNA GrimAge should be measured since they provide different lenses on methylome changes, similar to how doctors examine multiple biochemical markers like hemoglobin A1C and cystatin C. Exercise studies showed GrimAge detected benefits from four and a half hours of bicycling better than DunedinPACE. GrimAge detects inflammation. Clocks were built with AI and machine learning models, and the field is learning what interventions affect each clock.
The field needs surrogate endpoints for clinical trials. The Biomarker Consortium rigorously evaluates clocks, and ARPA-H funding supports both intervention studies and biomarker development for tracking longevity interventions. AI will likely improve clocks, though GrimAge from 2019 remains the best mortality predictor despite newer AI-based clocks like GrimAge version 3 and OMIC MH published in recent months.
Yamanaka factors, discovered by Shinya Yamanaka who won the Nobel Prize in 2006, are four transcription factor proteins that can revert any cell, including an 80-year-old's skin cell, to a pluripotent stem cell state. The 2013 pan-tissue clock paper showed Yamanaka factors reverse epigenetic age to a prenatal state, producing negative epigenetic age numbers. Researchers including Juan Carlos Izpisua Belmonte, Manuel Serrano, and David Sinclair have worked on briefly interrupted reprogramming to rejuvenate organs while maintaining cell identity.
David Sinclair's clinical trial using adeno-associated virus to deliver reprogramming factors to the eye for optic nerve regeneration is scheduled to begin in 2026. Companies must determine appropriate deployment conditions while ensuring safety. Reprogramming does not remove all damage types. Somatic mutations in DNA persist, and telomere length is not restored. Certain cytokines remain unreversed. Mitochondria become healthier, though mitochondrial DNA effects are unclear. Stem cells are rejuvenated.
Methylation clocks detect benefits of interrupted reprogramming in some organs like skin and muscle but not all. Researchers must measure organ function tests to establish functional restoration. Gene expression reverts to more youthful profiles, though building clocks based on gene expression has proven difficult. Mesenchymal markers indicate epithelial cells lose their identity with age partly due to inflammatory signals. Oxidative phosphorylation serves as another readout of cellular youth.
Somatic mutations persist in induced pluripotent stem cells because DNA changes cannot be addressed through reprogramming alone.
Somatic mutations accumulate in all cells throughout the body as people age. While cancer is often caused by somatic mutations, the question remains whether these mutations contribute to biological aging in general. Most somatic mutations have zero consequence because they do not occur in critical regulatory regions of genes or promoters. The field remains split on the importance of somatic mutations for aging, with some researchers viewing them as hugely important and others considering them negligible.
Even if somatic mutations could be completely stopped through perfect therapy or CRISPR-based correction, aging would still occur. Aging happens at multiple levels beyond the genome, including the epigenome, transcriptome, and proteome. Protein aggregation, for example, may occur independently of somatic mutations or methylation changes. There are 12 hallmarks of aging, and genome stability represents only one of them.
Stopping all somatic mutations would slow aging but would not prevent it entirely. Damage accumulation occurs across many biological systems, and addressing damage at one level still leaves the other eleven hallmarks to be managed.
Targeted interventions on individual organs could produce broad benefits. A hypothetical pill that prevents sarcopenia and maintains muscle strength might increase healthspan by five years through systemic effects. Resistance training is a validated intervention that helps maintain and increase muscle mass, which is strongly linked to both life expectancy and quality of life.
When considering an 85-year-old receiving such an intervention, the question arises whether restoring muscle function would extend lifespan by five years, given that other organs such as the heart may continue aging at different rates. Organs within the same individual age at different rates, creating individual variation in aging patterns.
Methylation clocks and protein markers can now provide readouts of different organ functions. These biomarkers allow diagnosis of which organs are aging faster or functioning suboptimally. The vision for Medicine 2.0 and preventative medicine involves measuring multiple organ-specific readouts, identifying problems early, and applying targeted interventions to restore function.
Genetic variants such as SNPs and polygenic risk scores show associations with various disorders, but these effects are generally minute. The famous APOE4 variant has a strong association with Alzheimer's disease, yet many people carrying APOE4 never develop the disease, and many people with Alzheimer's lack the APOE4 allele. Lifestyle factors such as walking 10,000 steps daily can dwarf the effects of most genetic risk variants.
Methylation patterns provide a far stronger signal than SNPs. Epigenetics is an order of magnitude more informative than genetics. Organ-specific epigenetic clocks offer additional resolution beyond standard biochemical markers such as C-reactive protein, HbA1c, or lipid levels.
At age 58, a PhenoAge result showed a biological age 13 years younger than chronological age. Organ-specific clocks have not yet been tested personally. Genetic tests such as whole genome sequencing or SNP arrays were performed for ancestry purposes but are not considered highly informative for personal health decisions compared to other biomarkers.
Validated interventions form the core routine: omega-3 supplementation, multivitamin use, and high-dose creatine intake. Daily exercise consists of 30 minutes performed consistently as part of personal hygiene rather than as an optional activity. A cooling mattress was implemented based on podcast recommendations and appears to improve sleep quality, though placebo effects are acknowledged as potentially contributing.
Vitamin D is supplemented. Medication includes metformin (referred to as "carbos") for prediabetes resulting from decades of high chocolate consumption, along with statin therapy. CoQ10 (ubiquinol) supplementation is noted as potentially beneficial when taking statins because the medication affects the mevalonate pathway involved in CoQ10 synthesis.
The approach avoids taking large numbers of supplements, preferring interventions with credible evidence. Short-term psychological stress, such as deadline pressure, does not appear to affect epigenetic clocks based on available literature, providing a hopeful perspective compared to severe, prolonged stressors like childhood trauma or PTSD.
Epigenetic clock research and longevity interventions are shared publicly via X (formerly Twitter) under the handle @prof. The closing message emphasizes staying young, avoiding excessive stress, and enjoying life.
Keep FoundMyFitness in your library
Save the videos and channels worth coming back to, and find them again in one place.
